Edward Greeno, M.D.
Upcoming SlideShare
Loading in...5
×
 

Edward Greeno, M.D.

on

  • 350 views

Creating Survivors: A century of treatment advances in colorectal cancer

Creating Survivors: A century of treatment advances in colorectal cancer

Statistics

Views

Total Views
350
Views on SlideShare
349
Embed Views
1

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 1

http://localhost 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Edward Greeno, M.D. Edward Greeno, M.D. Presentation Transcript

  • Creating Survivors:A Century of Treatment Advances inColorectal Cancer Edward Greeno, MD Associate Professor of Medicine, University of Minnesota Medical Director, Masonic Cancer Clinic Executive Medical Director, UMPhysicians Cancer Care
  • 1900’s to 1960’s Surgery 2
  • 1965 to 1995 One Chemotherapy drug: 5-Fluorouracil Screening 3
  • Outcomes with 5-FU 30 years of progress Survival 6-12 months  Probable 1-2 mo improvement in survival (Fancy 5FU) (5FU) Ed finished fellowship Ed started kindergardenFrom:Lancet7/29/00
  • Screening Fecal Occult Blood testing randomized trials  MN: 48,000 annual 10%+ tests 33% lower CRC mortality  UK: 150,00 biennial 2%+ tests 15% lower CRC mortality  DN: 62,000 biennial 1%+ 18% lower CRC mortality 5
  • 1995 to Present Prevention Adjuvant Therapy Multiple new chemotherapies Personalized Medicine 6
  • Prevention Diet  Populations with low fat, high fiber diets rich in fruits and vegetables = lower risk  Patients after resection of colon cancer who follow good diet => lower risk of recurrence Exercise  Patientsafter resection of colon cancer who exercise regularly => lower risk of recurrence 7
  • Prevention in high riskpopulations Identification of high risk patients  Geneticscreening  Inflammatory bowel disease  Frequent polyps Regular colonscopy with resection of polyps => 50% risk reduction Resection of the colon => 90% reduction 8
  • Adjuvant Therapy Definition:Treatment added to primary curative therapy to improve cure rates Frequent recurrences after surgery  10-80% depending on stage Due to occult (tiny & not visible) spread 9
  • Adjuvant Therapy Chemotherapy can cure microscopic metastatic disease Studies in early 90’s show 20-30% risk reduction with 5FU Additionof Oxaliplatin improved reduction to 40-50% 10
  • NeoAdjuvant Therapy Using regimens prior to surgery Dramatic response rates allow curative- intent resection of previously inoperable patients. 11
  • New Drugs Oral agents allow easier adminstration New cytoxic agents improve control of metastatic disease Better understanding of cancer biology allows better identification of targets 12
  • Oral 5-FU 5-FU poor, highly variable bioavalibility  To work best needs long IV infusion UFT:  5FU congener plus Uracil  comparable to IV 5FU Ralitrexed  Probably less effective than IV 5FU Capecitabine (Xeloda) 13
  • Capecitabine vs Bolus IV 5FU  Van Cutsem et al, JCO 2001
  • Irinotecan vs Best Supportive Care 100% Irinotecan Best Supportive Care Survival After 50% failing 5FU 0% 6.5mo 11.5mo 18moCunningham, Lancet 1998
  • Oxaliplatin  Survival with Frontline Oxaliplatin/5FU 100% Oxaliplatin plus 5FU 5FU alone 50%From: 0%JCO 6 12 18 24 30 36 mo8/15/00
  • Cytotoxic chemotherapy ofColorectal Cancer: SummaryPercentSurvival 0 Drugs (but well enough for a study) 1 Drug 2 Drugs 50% 3 Drugs Time (mo) 12 14 16 18
  • New targeted agents Angiogenesis inhibitors EGFR Inhibitors
  • Angiogenesis Inhibitors The concept: A tumor must grow a blood supplyBerger, Nature Reviews 2003
  • VEGF Inhibition in Colon Ca
  • 4 months better The results Median SurvivalHurwitz, NEJM 2004
  • Epidermal Growth Factor Receptor Subfamily of growth receptors  EGFR, HER2/neu, HER3, HER4 Activation leads to:  Ras/MAPK/Cyclin-D1 activation  Cellproliferation  Angiogenesis, Inhibition of apoptosis, metastases Autocrine growth pathway frequently activated in human tumors
  • Epidermal Growth Factor ReceptorInhibition Ciardiello, Clin Can Res, 2001
  • Cetuximab-current dataSurvival benefit vs. BSC  After failure of conventional therapy  QOL of life also better NCI CTG CO.17 1.0 Jonker et al, NEJM 2007 0.8Overall CETUXIMABsurvival 0.6 BEST SUPPORTIVE CARE P=0.0046 0.4 0.2 0 6 12 18 24 Months
  • Epidermal Growth Factor ReceptorInhibition Ciardiello, Clin Can Res, 2001
  • Regorafenib Randomized study in colon cancer patients failing all other therapies  Survival improved 2 months 26 www.thelancet.com Vol 381 January 26, 2013
  • Aflibercept Complex molecule to block multiple pathways--1 month survival benefit 27 J Clin Oncol 30:3499-3506.
  • Drug Therapy of AdvancedColorectal Cancer:Impact of new agentsPercent 0 Drugs 4 DrugsSurvival 1 Drug 5 Drugs 2 Drugs 6 Drugs 3 Drugs 7 Drugs 50% Time (mo) 12 14 16 18 >30 months median
  • Personalized Medicine New tools create much more detailed information about individual patient tumors Allow more precise selection of therapy Most of the promise just beginning to be realized 29
  • Selecting patients for adjuvanttherapy Microsatellite instability (MSI)  Genetic alteration in some tumors  Predicts lower recurrence risk  Predicts less effect of chemotherapy Avoid chemotherapy in low risk patients with MSI Molecular predictors being developed for multiple cancers 30
  • Cetuximab-importance of KRASIf KRAS is mutated:Cetuximab never works  NCI CTG CO.17  Karepetis et al, NEJM 2008 31
  • New Therapies for Colon Cancer For 60 years all we had was surgery Inthe next 30 we learned to do screening and developed one chemotherapy drug Inthe past 15 we dramatically improved outcomes The next 5 years will eclipse all of that 32
  • Advances In the Pipeline Genetically Engineered Salmonella  Infects tumor cells  Induces immune destruction Minnelide—Plant derived drug  downregulates protective mechanisms in cancer cells Genetically engineered Adenovirus  Infect and destroy tumor cells 33
  • Salmonella-pIL2Colorectal livermetastases reduced inmice orally administeredSalmonella-IL2 vs.saline (control) orSalmonella-no-IL2.Developed By DanSaltzmanFirst in human Phase Istudy nearly completewith no significant ttoxicity
  • Minnelide vs. Pancreas Cancer Science Translational Medicine, 17 October 2012 Vol 4 Issue 156  Effective in mice even with Developed by Ashok fresh patient xenograft rather Saluja than cell line  Effective even when tumor First in human trial allowed to grow to massive to begin in June volume
  • AdenovirusDeveloped by Masato Yamamoto ControlsEffective inmouse xenograftmodel Modified virus First in human trial awaiting toxicity studies and funding